Merkel cell carcinoma (neuroendocrine carcinoma of the skin): a lecture with a brief overview of 19 cases and demonstration of two clinical observations
- Authors: Gurevich L.E.1, Grishina E.E.1
-
Affiliations:
- Moscow Regional Research and Clinical Institute (MONIKI)
- Issue: Vol 48, No 2 (2020)
- Pages: 125-139
- Section: LECTURE
- URL: https://almclinmed.ru/jour/article/view/1257
- DOI: https://doi.org/10.18786/2072-0505-2020-48-014
- ID: 1257
Cite item
Full Text
Abstract
The lecture deals with epidemiology, clinical morphological and genetic characteristics of a rare aggressive neuroendocrine carcinoma of the skin, or Merkel cell carcinoma (MC). We describe the algorithms for the differential diagnosis of these tumors and their treatment approaches, and focus on the main unresolved issues, such as delayed and erroneous diagnosis, the search for new diagnostic markers and targets for the development of more effective treatment methods. We provide a brief clinical and morphological analysis of 19 own observations of MC in 10 men and 9 women aged 40 to 85 years (57.9% of the patients were above 60 years, 31.6% from 50 to 60 years, and 10.5%, below 50 years). In 42.1% of the cases, the tumors were located in the head, in 15.8% in the limbs, and in 15.8% in the trunk and soft tissues; in the rest of the cases the primary tumor location was not identified. Only in 4 cases MC was diagnosed immediately; in all other cases, the initial diagnoses had been wrong. The diagnosis of MC was established after the analysis of medical files, histological and immunohistochemical biopsy studies and was confirmed by immunohistochemistry. All the tumors were expressing synaptophysin, chromogranin A, CD56; in all cases except one, cytokeratin 20 of the dote-like type, type 2A somatostatin receptors in 66.7%, nuclear survivin in 100%, p53 in 88.9%, CD117 in 57.1%. To illustrate the topic, we present 2 clinical observations of MC. The first case was an 82-year old man who had been living for a long time in the territory with increased sun radiation. A bright red tumor developed on his left upper eyelid, becoming gigantic (5 cm in diameter) within 2 months and bleeding. Despite the radical excision of the tumor, at 2 months after the surgery he developed local recurrence and metastases in regional lymph nodes. Thereafter, he underwent the orbital exenteration and lymphodissection of the affected lymph nodes. The second observation was a 63-year old man. At 10 years after he had had his renal transplant, he developed a mixed skin tumor on the anterior neck surface. The tumor was represented by MC and porocarcinoma with signs of squamous and sebaceous differentiation. These observations demonstrate MC rapid growth, its aggressive potential and such risk factors as prolonged high insolation and long-term drug immunosuppression after organ transplantation. Conclusion: At present, the rarity and low understanding of MC, its rapid growth, late diagnosis, aggressive biological potential and the lack of uniform treatment standards do not allow for cure in most such patients. The solution to the problem lies in the search for the cellular targets that would allow for the development of new effective targeted treatments for these aggressive tumors. In addition, integration of any results obtained in multicenter studies of the disease is essential.
About the authors
L. E. Gurevich
Moscow Regional Research and Clinical Institute (MONIKI)
Author for correspondence.
Email: larisgur@mail.ru
ORCID iD: 0000-0002-9731-3649
Larisa E. Gurevich - ScD in Biology, Professor, Leading Research Fellow, Department of Oncology.
61/2 Shchepkina ul., Moscow, 129110.
Tel.: +7 (495) 631 74 22.
Russian FederationE. E. Grishina
Moscow Regional Research and Clinical Institute (MONIKI)
Email: fake@neicon.ru
ORCID iD: 0000-0003-2668-9136
Elena E. Grishina - MD, PhD, Professor, Chief Research Fellow, Department of Oncology.
61/2 Shchepkina ul., Moscow, 129110.
Russian FederationReferences
- Becker JC, Stang A, DeCaprio JA, Cerroni L, Lebbe C, Veness M, Nghiem P. Merkel cell carcinoma. Nat Rev Dis Primers. 2017;3:17077. doi: 10.1038/nrdp.2017.77.
- Lebbe C, Becker JC, Grob JJ, Malvehy J, Del Marmol V, Pehamberger H, Peris K, Saiag P, Middleton MR, Bastholt L, Testori A, Stratigos A, Gar-be C; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC). Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. Eur J Cancer. 2015;51(16):2396-403. doi: 10.1016/j.ejca.2015.06.131.
- Toker C. Trabecular carcinoma of the skin. Arch Dermatol. 1972;105(1):107-10.
- Tang CK, Toker C. Trabecular carcinoma of the skin: an ultrastructural study. Cancer. 1978;42(5):2311-21. doi: 10.1002/1097-0142(197811)42:5<2311::aid-cn-cr2820420531>3.0.co;2-l.
- Merkel F. Tastzellen und Tastkorperchen bei den Haustieren und beim Menschen. Arch Mikrosk Anat 11: 636-52.
- De Wolff-Peeters C, Marien K, Mebis J, Desmet V. A cutaneous APUDoma or Merkel cell tumor? A morphologically recognizable tumor with a biological and histological malignant aspect in contrast with its clinical behavior. Cancer. 1980;46(8):1810-6. doi: 10.1002/1097-0142(19801015)46:8<1810::aid-cncr2820460819>3.0.co;2-7.
- Tilling T, Moll I. Which are the cells of origin in merkel cell carcinoma? J Skin Cancer. 2012;2012:680410. doi: 10.1155/2012/680410.
- Erovic I, Erovic BM. Merkel cell carcinoma: the past, the present, and the future. J Skin Cancer. 2013;2013:929364. doi: 10.1155/2013/929364.
- Jaeger T, Ring J, Andres C. Histological, im-munohistological, and clinical features of merkel cell carcinoma in correlation to merkel cell polyomavirus status. J Skin Cancer. 2012;2012:983421. doi: 10.1155/2012/983421.
- Pulitzer M. Merkel Cell Carcinoma. Surg Pathol Clin. 2017;10(2):399-408. doi: 10.1016/j.path.2017.01.013.
- Хайрутдинов ВР. Рак из клеток Меркеля. Практическая онкология. 2012;13(2):107-13.
- Albores-Saavedra J, Batich K, Chable-Monte-ro F, Sagy N, Schwartz AM, Henson DE. Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study. J Cutan Pathol. 2010;37(1):20-7. doi: 10.1111/j.1600-0560.2009.01370.x.
- Higaki-Mori H, Kuwamoto S, Iwasaki T, Kato M, Murakami I, Nagata K, Sano H, Horie Y, Yoshida Y, Yamamoto O, Adachi K, Nanba E, Hayashi K. Association of Merkel cell polyomavirus infection with clinicopathological differences in Merkel cell carcinoma. Hum Pathol. 2012;43(12):2282-91. doi: 10.1016/j.humpath.2012.04.002.
- Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319(5866):1096-100. doi: 10.1126/science.1152586.
- Liu W, MacDonald M, You J. Merkel cell polyomavirus infection and Merkel cell carcinoma. Curr Opin Virol. 2016;20:20-7. doi: 10.1016/j.coviro.2016.07.011.
- Kuwamoto S, Higaki H, Kanai K, Iwasaki T, Sano H, Nagata K, Kato K, Kato M, Murakami I, Horie Y, Yamamoto O, Hayashi K. Association of Merkel cell polyomavirus infection with morphologic differences in Merkel cell carcinoma. Hum Pathol. 2011;42(5):632-40. doi: 10.1016/j.humpath.2010.09.011.
- Morais FS, Bonilha CS, Carraro E. Involvement of Merkel cell polyomavirus in the etiology and pathogenesis of Merkel cell carcinoma: A systematic review. Cancer Res J. Special Issue: Lifestyle and Cancer Risk. 2014;2(6-1):1-10. doi: 10.11648/j.crj.s.2014020601.11.
- Cimino PJ, Robirds DH, Tripp SR, Pfeifer JD, Abel HJ, Duncavage EJ. Retinoblastoma gene mutations detected by whole exome sequencing of Merkel cell carcinoma. Mod Pathol. 2014;27(8):1073-87. doi: 10.1038/mod-pathol.2013.235.
- Pulitzer MP, Brannon AR, Berger MF, Louis P, Scott SN, Jungbluth AA, Coit DG, Brownell I, Busam KJ. Cutaneous squamous and neuroendocrine carcinoma: genetically and immunohistochemically different from Merkel cell carcinoma. Mod Pathol. 2015;28(8):1023-32. doi: 10.1038/modpathol.2015.60.
- DeCaprio JA. Merkel cell polyomavirus and Merkel cell carcinoma. Philos Trans R Soc Lond B Biol Sci. 2017;372(1732):20160276. doi: 10.1098/rstb.2016.0276.
- Capella C, Marando A, Longhi E, Bernasconi B, Finzi G, Parravicini C, Sessa F, La Rosa S. Primary gastric Merkel cell carcinoma harboring DNA polyomavirus: first description of an un usual high-grade neuroendocrine carcinoma. Hum Pathol. 2014;45(6):1310-4. doi: 10.1016/j.humpath.2014.01.019.
- Gould VE, Moll R, Moll I, Lee I, Franke WW. Neuroendocrine (Merkel) cells of the skin: hyperplasias, dysplasias, and neoplasms. Lab Invest. 1985;52(4):334-53.
- Pan Z, Chen YY, Wu X, Trisal V, Wilczynski SP, Weiss LM, Chu PG, Wu H. Merkel cell carcinoma of lymph node with unknown primary has a significantly lower association with Merkel cell polyomavirus than its cutaneous counterpart. Mod Pathol. 2014;27(9):1182-92. doi: 10.1038/modpathol.2013.250.
- Heath M, Jaimes N, Lemos B, Mostaghimi A, Wang LC, Penas PF, Nghiem P. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol. 2008;58(3):375-81. doi: 10.1016/j.jaad.2007.11.020.
- Lai JH, Fleming KE, Ly TY, Pasternak S, Godlewski M, Doucette S, Walsh NM. Pure versus combined Merkel cell carcinomas: immunohistochemical evaluation of cellular proteins (p53, Bcl-2, and c-kit) reveals significant overexpression of p53 in combined tumors. Hum Pathol. 2015;46(9):1290-6. doi: 10.1016/j.humpath.2015.05.008.
- Liang E, Brower JV, Rice SR, Buehler DG, Saha S, Kimple RJ. Merkel cell carcinoma analysis of outcomes: A 30-year experience. PLoS One. 2015;10(6):e0129476. doi: 10.1371/journal. pone.0129476.
- Paulson KG, Lemos BD, Feng B, Jaimes N, Penas PF, Bi X, Maher E, Cohen L, Leonard JH, Granter SR, Chin L, Nghiem P. Array-CGH reveals recurrent genomic changes in Merkel cell carcinoma including amplification of L-Myc. J Invest Dermatol. 2009;129(6):1547-55. doi: 10.1038/jid.2008.365.
- Leonard JH, Hayard N. Loss of heterozygosity of chromosome 13 in Merkel cell carcinoma. Genes Chromosomes Cancer. 1997;20(1):93-7. doi: 10.1002/(sici)1098-2264(199709)20:1<93::aid-gcc14>3.0.co;2-g.
- Tarantola TI, Vallow LA, Halyard MY, Weenig RH, Warschaw KE, Weaver AL, Roenigk RK, Brewer JD, Otley CC. Unknown primary Merkel cell carcinoma: 23 new cases and a review. J Am Acad Dermatol. 2013;68(3):433-40. doi: 10.1016/j.jaad.2012.07.035.
- Harms PW, Collie AM, Hovelson DH, Cani AK, Verhaegen ME, Patel RM, Fullen DR, Omata K, Dlugosz AA, Tomlins SA, Billings SD. Next generation sequencing of Cytokeratin 20-negative Merkel cell carcinoma reveals ultraviolet-signature mutations and recurrent TP53 and RB1 inactivation. Mod Pathol. 2016;29(3):240-8. doi: 10.1038/modpathol.2015.154.
- Kontis E, Vezakis A, Pantiora E, Stasinopou-lou S, Polydorou A, Voros D, Fragulidis GP. Merkel cell carcinoma of unknown primary site; case presentation and review of the literature. Ann Med Surg (Lond). 2015;4(4):434-7. doi: 10.1016/j.amsu.2015.10.013.
- Lilo MT, Chen Y, LeBlanc RE. INSM1 Is More Sensitive and Interpretable than Conventional Immunohistochemical Stains Used to Diagnose Merkel Cell Carcinoma. Am J Surg Pathol. 2018;42(11):1541-8. doi: 10.1097/PAS.0000000000001136.
- Wu J, Wang X, Lin C, Yu S, Cai L, Gao Z. Carcinosarcoma of native renal pelvis in recipient after a renal transplant: a case report. World J Surg Oncol. 2014;12:407. doi: 10.1186/1477-7819-12-407.
- Tuzuner A, Çakir F, Akyol C, Çelebi ZK, Ceylaner S, Ceylaner G, Sengul S, Keven K. Nephron-sparing surgery for renal cell carcinoma of the allograft after renal transplantation: report of two cases. Transplant Proc. 2013;45(3):958-60. doi: 10.1016/j.transproceed.2013.02.054.
- Kanitakis J, Euvrard S, Chouvet B, Butnaru AC, Claudy A. Merkel cell carcinoma in organ-transplant recipients: report of two cases with unusual histological features and literature review. J Cutan Pathol. 2006;33(10):686-94. doi: 10.1111/j.1600-0560.2006.00529.x.
- Koljonen V, Sahi H, Bohling T, Makisalo H. Post-transplant Merkel Cell Carcinoma. Acta Derm Venereol. 2016;96(4):442-7. doi: 10.2340/00015555-2284.
- Clarke CA, Robbins HA, Tatalovich Z, Lynch CF, Pawlish KS, Finch JL, Hernandez BY, Fraumeni JF Jr, Madeleine MM, Engels EA. Risk of merkel cell carcinoma after solid organ transplantation. J Natl Cancer Inst. 2015;107(2):dju382. doi: 10.1093/jnci/dju382.
- Garrett GL, Zargham H, Schulman JM, Ja-farian F, Yu SS, Arron ST. Merkel cell carcinoma in organ transplant recipients: Case reports and review of the literature. JAAD Case Rep. 2015;1(6):S29-32. doi: 10.1016/j.jdcr.2015.09.017.
- Kempf W, Mertz KD, Hofbauer GF, Tinguely M. Skin cancer in organ transplant recipients. Pathobiology. 2013;80(6):302-9. doi: 10.1159/000350757.
- Kim J, McNiff JM. Nuclear expression of sur-vivin portends a poor prognosis in Merkel cell carcinoma. Mod Pathol. 2008;21(6):764-9. doi: 10.1038/modpathol.2008.61.
- Tarantola TI, Vallow LA, Halyard MY, Weenig RH, Warschaw KE, Grotz TE, Jakub JW, Roenigk RK, Brewer JD, Weaver AL, Otley CC. Prognostic factors in Merkel cell carcinoma: analysis of 240 cases. J Am Acad Dermatol. 2013;68(3):425-32. doi: 10.1016/j.jaad.2012.09.036.
- Fleming KE, Ly TY, Pasternak S, Godlewski M, Doucette S, Walsh NM. Support for p63 expression as an adverse prognostic marker in Merkel cell carcinoma: report on a Canadian cohort. Hum Pathol. 2014;45(5):952-60. doi: 10.1016/j.humpath.2013.12.008.
- Sihto H, Kukko H, Koljonen V, Sankila R, Boh-ling T, Joensuu H. Merkel cell polyomavirus infection, large T antigen, retinoblastoma protein and outcome in Merkel cell carcinoma. Clin Cancer Res. 2011;17(14):4806-13. doi: 10.1158/1078-0432.CCR-10-3363.
- Bhatia S, Storer BE, Iyer JG, Moshiri A, Parvathaneni U, Byrd D, Sober AJ, Sondak VK, Gershenwald JE, Nghiem P. Adjuvant radiation therapy and chemotherapy in Merkel cell carcinoma: survival analyses of 6908 cases from the National Cancer Data Base. J Natl Cancer Inst. 2016;108(9):djw042. doi: 10.1093/jnci/djw042.
- Tseng J, Dhungel B, Mills JK, Diggs BS, Weer-asinghe R, Fortino J, Vetto JT. Merkel cell carcinoma: what makes a difference? Am J Surg. 2015;209(2):342-6. doi: 10.1016/j.amj-surg.2014.06.013.46.
- Andea AA, Patel R, Ponnazhagan S, Kumar S, DeVilliers P, Jhala D, Eltoum IE, Siegal GP. Merkel cell carcinoma: correlation of KIT expression with survival and evaluation of KIT gene mutational status. Hum Pathol. 2010;41(10):1405-12. doi: 10.1016/j.humpath.2010.02.010.
- Erovic BM, Al Habeeb A, Harris L, Goldstein DP, Ghazarian D, Irish JC. Significant overexpression of the Merkel cell polyomavirus (MCPyV) large T antigen in Merkel cell carcinoma. Head Neck. 2013;35(2):184-9. doi: 10.1002/hed.22942.
- Krasagakis K, Fragiadaki I, Metaxari M, Kruger-Krasagakis S, Tzanakakis GN, Stathopoulos EN, Eberle J, Tavernarakis N, Tosca AD. KIT receptor activation by autocrine and paracrine stem cell factor stimulates growth of merkel cell carcinoma in vitro. J Cell Physiol. 2011;226(4):1099-109. doi: 10.1002/jcp.22431.
- Swick BL, Srikantha R, Messingham KN. Specific analysis of KIT and PDGFR-alpha expression and mutational status in Merkel cell carcinoma. J Cutan Pathol. 2013;40(7):623-30. doi: 10.1111/cup.12160.
- Waltari M, Sihto H, Kukko H, Koljonen V, Sanki-la R, Bohling T, Joensuu H. Association of Merkel cell polyomavirus infection with tumor p53, KIT, stem cell factor, PDGFR-alpha and survival in Merkel cell carcinoma. Int J Cancer. 2011;129(3):619-28. doi: 10.1002/ijc.25720.
- Samlowski WE, Moon J, Tuthill RJ, Heinrich MC, Balzer-Haas NS, Merl SA, DeConti RC, Thompson JA, Witter MT, Flaherty LE, Sondak VK. A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group study (S0331). Am J Clin Oncol. 2010;33(5):495-9. doi: 10.1097/COC.0b013e3181b9cf04.
- Arora R, Shuda M, Guastafierro A, Feng H, Toptan T, Tolstov Y, Normolle D, Vollmer LL, Vogt A, Domling A, Brodsky JL, Chang Y, Moore PS. Survivin is a therapeutic target in Merkel cell carcinoma. Sci Transl Med. 2012;4(133):133ra56. doi: 10.1126/sci-translmed.3003713.
- Xie H, Lee L, Caramuta S, Hoog A, Browaldh N, Bjornhagen V, Larsson C, Lui WO. MicroRNA expression patterns related to merkel cell polyomavirus infection in human merkel cell carcinoma. J Invest Dermatol. 2014;134(2):507-17. doi: 10.1038/jid.2013.355.
- Dresang LR, Guastafierro A, Arora R, Nor-molle D, Chang Y, Moore PS. Response of Merkel cell polyomavirus-positive merkel cell carcinoma xenografts to a survivin inhibitor. PLoS One. 2013;8(11):e80543. doi: 10.1371/journal.pone.0080543.
- Gomez B, He L, Tsai YC, Wu TC, Viscidi RP, Hung CF. Creation of a Merkel cell polyomavirus small T antigen-expressing murine tumor model and a DNA vaccine targeting small T antigen. Cell Biosci. 2013;3(1):29. doi: 10.1186/2045-3701-3-29.
- Sahi H, Koljonen V, Kavola H, Haglund C, Tuki-ainen E, Sihto H, Bohling T. Bcl-2 expression indicates better prognosis of Merkel cell carcinoma regardless of the presence of Merkel cell polyomavirus. Virchows Arch. 2012;461(5):553-9. doi: 10.1007/s00428-012-1310-3.
- Делекторская ВВ, Орлова КВ, Демидов ЛВ. Рецепторы соматостатина 2- и 5-го подтипов в карциноме из клеток Меркеля: иммуногистохимическое исследование. Технологии живых систем. 2015;(2):56-62.
- Orlova KV, Delektorskaya VV, Vishnevskaya YV, Kondratieva TT, Orel NF, Markovich AA, Demidov LV, Subramanian S. Somatostatin receptor type 2 expression in Merkel cell carcinoma as a prognostic factor. J Eur Acad Dermatol Vene-reol. 2018;32(6):e236-7. doi: 10.1111/jdv.14769.
- di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L, Zilembo N, di Leo A. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer. 1996;77(2):402-8. doi: 10.1002/(SICI)1097-0142(19960115)77:2<402::AID-CNCR25>3.0.CO;2-4.
- Fakiha M, Letertre P, Vuillez JP, Lebeau J. Remission of Merkel cell tumor after somatostatin analog treatment. J Cancer Res Ther. 2010;6(3):382-4. doi: 10.4103/0973-1482.73352.
- von der Grun J, Winkelmann R, Meissner M, Wieland U, Silling S, Martin D, Fokas E, Rodel C, Rodel F, Balermpas P. Merkel cell polyoma viral load and intratumoral CD8+ lymphocyte infiltration predict overall survival in patients with Merkel cell carcinoma. Front Oncol. 2019;9:20. doi: 10.3389/fonc.2019.00020.
- Colunga A, Pulliam T, Nghiem P. Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes. Clin Cancer Res. 2018;24(9):2035-43. doi: 10.1158/1078-0432.CCR-17-0439.
- Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP, Friedlander PA, Kluger HM, Kohrt HE, Lundgren L, Margolin K, Mitchell A, Olencki T, Pardoll DM, Reddy SA, Shantha EM, Sharfman WH, Sharon E, Shemanski LR, Shi-nohara MM, Sunshine JC, Taube JM, Thompson JA, Townson SM, Yearley JH, Topalian SL, Cheever MA. PD-1 blockade with pembroli-zumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016;374(26):2542-52. doi: 10.1056/NEJMoa1603702.
- Bichakjian CK, Olencki T, Aasi SZ, Alam M, Andersen JS, Blitzblau R, Bowen GM, Contreras CM, Daniels GA, Decker R, Farma JM, Fisher K, Gastman B, Ghosh K, Grekin RC, Grossman K, Ho AL, Lewis KD, Loss M, Lydiatt DD, Messina J, Nehal KS, Nghiem P, Puzanov I, Schmults CD, Shaha AR, Thomas V, Xu YG, Zic JA, Hoffmann KG, Engh AM. Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16(6):742-74. doi: 10.6004/jnccn.2018.0055.
- Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbe C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, Nghiem P. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, sin-gle-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374-85. doi: 10.1016/ S1470-2045(16)30364-3.
- Desch L, Kunstfeld R. Merkel cell carcinoma: chemotherapy and emerging new therapeutic options. J Skin Cancer. 2013;2013:327150. doi: 10.1155/2013/327150.
- Коровин СИ, Колесниченко ВА, Кукушкина МН, Паливец АЮ, Остафийчук ВВ. Карцинома Меркеля: клиника, диагностика и лечение. Клiнiчна Онкологiя. 2014;13( 1 ):1 -6. [Интернет]. Доступно на: https://www.clinicaloncology.com.ua/wp/wp-content/uploads/2014/04/341.pdf.
- Казанцева ИА, Гуревич ЛЕ, Бобров МА. Редкие клинические наблюдения «комбинированных» карцином кожи у реципиентов аллотрансплантата трупной почки. Альманах клинической медицины. 2018;46(4):367-73. doi: 10.18786/2072-0505-2018-46-4-367-373.
Supplementary files
![](/img/style/loading.gif)